Fred Saad
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Prostate Cancer Treatment and Research
Strong evidence · 9 supporting papers · latest 2026
Renal cell carcinoma treatment
Strong evidence · 4 supporting papers · latest 2026
Prostate Cancer Diagnosis and Treatment
Strong evidence · 8 supporting papers · latest 2026
Testicular diseases and treatments
Solid evidence · 1 supporting paper · latest 2026
Cancer, Lipids, and Metabolism
Solid evidence · 3 supporting papers · latest 2026
Bladder and Urothelial Cancer Treatments
Solid evidence · 3 supporting papers · latest 2026
Cancer survivorship and care
Solid evidence · 2 supporting papers · latest 2026
Bone health and treatments
Solid evidence · 1 supporting paper · latest 2026
Publications (15)
Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer
2026DOIPMID 42542968
Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era
2026DOIPMID 42552493
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
2026DOI
Role of cytoreductive nephrectomy in metastatic medullary renal cell carcinoma: controlled analysis
2026DOIPMID 42762265
Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy
2026DOIPMID 42557188
Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer
2026DOIPMID 42617299
ASO Visual Abstract: Risk-adapted use of adjuvant systemic therapy after nephrectomy for renal cell carcinoma: a population-based study in the post-approval era
2026DOIPMID 42573667
First-in-human evaluation of 225Ac-PSMA-Trillium™ (BAY 3563254; 225Ac felivotide mopaxetan) in metastatic castration-resistant prostate cancer: the phase 1 PAnTHA study
2026DOI
Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial
2026DOIPMID 42586872
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
2026DOIPMID 42595654
Contemporary Trends in Primary Retroperitoneal Lymph Node Dissection in Nonseminomatous Germ Cell Tumors
2026DOIPMID 42705957
ASO Visual Abstract: Cancer-Specific Mortality in Rare Histologic Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy
2026DOIPMID 42704566
Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial
2026DOIPMID 42665513
ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care
2026DOIPMID 42663775
Managing Metabolic Syndrome and Prostate Cancer
2026DOIPMID 42593778
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: OpenAlex · retrieved 2026-09-29